According to an announcement by an international biotechnology company in China, Clover Biopharmaceuticals, thriving to develop new biological therapies, the first-ever cancer patient suffering from malignant pleural effusions was admitted in Australia in a fully human TRAIL-Trimer fusion protein, the phase I of SCB-313 trial. Five clinical studies to evaluate SCB-13 and recruit patients from Australia and China.
Director of Pleural Medicine at Sir Charles Gairdner Hospital, Perth, Australia, Dr. Y.C.Gary Lee, said that cancer patients and clinicians from all over the world are facing a great deal of problems because of MPE.
Dr. Lee’s unit and several other areas in Australia are working on the harmlessness, sustainability, pharmacokinetics, and the efficiency of the intrapleural administered SCB-313 as these factors were to be evaluated by the escalated dose trail of the open-label Phase I.
The Executive Vice President of Global Clinical Development, Clover, Dr. Min Dong, said that it is their pleasure that these top-rank scientists are going to co-work with Clover. Dr. Min Dong hopes to bring SCB-313, the new and efficient cancer therapy, to the patients around the world, as they have already brought it in many countries.
The chairman and co-founder of clover, Dr. Peng Liang, said that TRAIL can kill a variety of tumor cells and thus it has been considered a go-to therapy for cancer. He said that SCB-313 that uses Clover’s licensed Trimer-Tag © technology targets this cellular death powerfully. Dr. Peng believes that their Research and Development result shows that the best TRAIL-based therapy is SCB-313. Clover is working to find new therapies for intracavitary cancer treatment.
The international biopharmaceutical company, Clover Biopharmaceuticals, was founded to carry research in the field of innovative biological therapies and work for the development and marketing of the field, especially on oncology and autoimmune diseases. To make novel biologics, targeting trimerization-dependent trails, Trimer-Tag ©, the company’s licensed technology platform is used.
Tags : Phase 1 SCB-313, Malignant Pleural Effusion , Treatment , Clover Biopharmaceuticals ,